The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2018 | Midostaurin and quizartinib: improving survival and day-to-day life in AML
Alexander Perl, MD, of the University of Pennsylvania, Philadelphia, PA, discusses the effectiveness of drugs currently on the market to treat acute myeloid leukemia (AML) at the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX. Dr Perl explains how the FLT3 inhibitors midostaurin and quizartinib have improved the overall survival of AML patients, and protect against relapse better than standard therapy. With tolerable side effects, he excitedly disccusses the the future of AML treatments which do not affect the patient’s day to day life.
